Pathological complete response · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in pathological complete response (pCR): breast and axillary nodes compared with non‐capecitabine‐containing regimens (high certainty).
1 finding from 1 review
Overall Survival** · locally advanced or metastatic breast cancer
PARPi‐containing regimen showed no clear difference in overall Survival** compared with non‐PARPi regimen (high certainty).
1 finding from 1 review
Progression‐free survival · locally advanced or metastatic breast cancer
PARPi‐containing regimen leads to lower progression Free Survival** compared with non‐PARPi regimen (high certainty).
1 finding from 1 review
Response rate · locally advanced or metastatic breast cancer
PARPi‐containing regimen may leads to higher response Rate compared with non‐PARPi regimen (low certainty).
1 finding from 1 review
Grade ≥3 AEs · locally advanced or metastatic breast cancer
PARPi‐containing regimen showed no clear difference in grade ≥3 AEs compared with non‐PARPi regimen (moderate certainty).
1 finding from 1 review
Need for analgesic prescription for pain (supplemental analgesic requirements) · breast cancer surgery
Paravertebral anaesthesia with or without sedation may leads to lower postoperative analgesic requirement compared with general anaesthesia (low certainty).
1 finding from 1 review
Number of patients with postoperative nausea and vomiting (postoperative care unit) · breast cancer surgery
Paravertebral anaesthesia with or without sedation probably leads to lower postoperative nausea and vomiting (PONV) compared with general anaesthesia (moderate certainty).
1 finding from 1 review
Postoperative pain at 2 hours · breast cancer surgery
1 finding from 1 review
Postoperative pain at 24 hours on rest · breast cancer surgery
1 finding from 1 review
Postoperative pain at 6 hours on movement · breast cancer surgery
1 finding from 1 review
Pain (VAS scores) on movement at postoperative day 1 Scale from: 0 to 10. · breast cancer surgery
1 finding from 1 review
All‐cause mortality · breast cancer surgery
1 finding from 1 review
Intervention not reported
Breast cancer mortality ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence ‐ AIs · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence (loco‐regional) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence (distance) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Incidence of a secondary primary breast cancer (e.g. in the contralateral breast) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)/unknown) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Prevention: incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor) or not receiving endocrine therapy…
1 finding from 1 review